v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows from operating activities:    
Net income (loss) $ (28,428) $ 15,315
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization expense 4,002 3,354
Stock-based compensation expense 7,048 7,080
Provision for inventory obsolescence 330 378
Net amortization of premiums and accretion of discounts on marketable securities 327 (641)
Loss on disposal of property and equipment 12 133
Gain on sale of Desktop Portfolio, net of transaction costs   (56,128)
Provision for credit losses 254  
Change in fair value of contingent consideration 12,518 19,999
Amortization of debt issuance costs 40  
Deferred tax liabilities (104)  
Changes in operating assets and liabilities, net of business combinations:    
Accounts receivable, net (5,449) 546
Inventory (2,077) (5,462)
Prepaid expenses and other current assets 4,596 (2,237)
Other long-term assets (171) 189
Accounts payable and accrued expenses 6,073 (5,423)
Deferred revenue 2,522 (2,142)
Right-of-use operating lease assets 575 1,563
Operating lease liabilities (503) (1,531)
Net cash provided by (used in) operating activities 1,565 (25,007)
Cash flows from investing activities:    
Purchases of property and equipment (267) (961)
Purchases of marketable securities (35,071) (54,276)
Acquisition of businesses, net of cash acquired (12,523) (2,000)
Proceeds from sale of Desktop Portfolio   69,909
Proceeds from maturities of marketable securities 41,500 31,265
Net cash provided by (used in) investing activities (6,361) 43,937
Cash flows from financing activities:    
Payments for withholding taxes on vested awards (2,422) (698)
Proceeds from issuance of common stock 1,852 415
Payment of deferred financing costs (121)  
Net cash used in financing activities (691) (283)
Effect of foreign exchange rate changes on cash and cash equivalents (103) 27
Net increase (decrease) in cash, cash equivalents and restricted cash (5,590) 18,674
Cash, cash equivalents and restricted cash at beginning of period 70,592 44,203
Cash, cash equivalents and restricted cash at end of period 65,002 62,877
Supplemental disclosure of noncash investing and financing information:    
Transfers of inventory to property and equipment 1,089 $ 513
NIRLAB    
Supplemental disclosure of noncash investing and financing information:    
Fair value of common stock issued for acquisitions and in settlement of contingent consideration 1,726  
Red Wave    
Supplemental disclosure of noncash investing and financing information:    
Fair value of common stock issued for acquisitions and in settlement of contingent consideration $ 25,323